Moderna and Merck's experimental cancer vaccine has delivered positive results in a late-stage melanoma trial, giving a major boost to personalized mRNA treatments as rivals including BioNTech and Roche pursue similar approaches.
Companies on the S&P 500 are closing out one of their strongest earnings seasons in years, with part of the extraordinary growth coming from soaring valuations of artificial intelligence companies.
Among Americans who spend money on sports, 47% said they have gone into debt to pay for those expenses, like tickets, streaming subscriptions, and merchandise.
Another batch of shares held by early investors and employees became eligible for trading Thursday, putting Elon Musk's newly public space company through another major test.
Jesse Williams, CEO of Rezerra, discusses acquiring 49 battery energy storage systems with a 20-year long-term operator commitment to stabilize grid reliability.
Revenue rose 9% from a year earlier to 268.95 billion Chinese yuan, or roughly $39.7 billion, narrowly exceeding the 268.88 billion yuan expected by analysts.
The company said it is speeding up its 40 trillion won, or roughly $28.7 billion, share repurchase and cancellation program while targeting a significant increase in shareholder returns.
Public opposition to data centers is becoming a political issue across the U.S., raising concerns about whether technology companies can build the infrastructure needed for their AI expansion plans.
An elevated PSA reading triggers a modern prostate cancer workup built on multiparametric MRI, targeted biopsies, and active surveillance. Dr. Jitesh Patel of Advanced Urology explains the new pathway.